Chargement en cours...
Ramucirumab: preclinical research and clinical development
Ramucirumab (IMC-1121B, LY3009806), a fully humanized monoclonal antibody directed against the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), is a new therapeutic option that selectively inhibits the human VEGFR-2 with a much greater affinity than its natural ligand...
Enregistré dans:
| Publié dans: | Onco Targets Ther |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218907/ https://ncbi.nlm.nih.gov/pubmed/25378934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S61132 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|